Identification | Back Directory | [Name]
(2R,3S)-2-{(1R)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY}-3-(4-FLUOROPHENYL)MORPHOLINE HYDROCHLORIDE | [CAS]
171482-05-6 | [Synonyms]
Aprepitant HCl Aprepitant intermediate (2R,3S)-2-((R)-1-(3,5-Bi APREPITANT INTERMEDIATES Aprepitant M2 Matabolite Aprepitant Stage-II (Impurity-A) Aprepitant Impurity 1 Enantiomer HCl Aprepitant M2 Metabolite (1R, 2R, 3S) (2R, 3S)-2-(1R)-1-(3, 5-BIS (TRIFLUOROMETHYL)-3-(4-FLUOROPHENYL) MORPHOLINE HYDROCHLORIDE (2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)-ethoxy)-3-(4-fluorophenyl)morpholine hydroch 2R 3S)-2-(1R)-1-3,5-Bis(Trifluoromethyl)Phenyl)Ethoxy)-3-(4Fluoropheny)Morpholine Hydrochloride (2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)-ethoxy)-3-(4-fluorophenyl)morpholine hydrochlor (2R,3S)-2-((R)-1-(3,5-Bis(trifluoroMethyl)phenyl)ethoxy)-3-(4-fluorophenyl)Morpholine hydrochloride (2R,3S)-2-{(1R)-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY}-3-(4-FLUOROPHENYL)MORPHOLINE HYDROCHLORIDE Morpholine,2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-,hydrochloride, (2R,3S)- (2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)Morpholine hydrochloride (1:1) Morpholine, 2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-, hydrochloride (1:1), (2R,3S)- Aprepitant int-3 (2R,3S)-2-((R)-1-(3,5-Bis(trifluoroMethyl)phenyl)ethoxy)-3-(4-fluorophenyl)Morpholine hydrochloride | [EINECS(EC#)]
691-262-0 | [Molecular Formula]
C20H18F7NO2.HCl | [MDL Number]
MFCD13183776 | [MOL File]
171482-05-6.mol | [Molecular Weight]
473.82 |
Hazard Information | Back Directory | [Uses]
(2R,3S)-2-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholine hydrochloride is an important pharmaceutical intermediate compound whose reaction unit is used in the synthesis of aprepitant intermediates. Arepitane is a neurokinin-1 antagonist analogue.
It is used for the management and prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) in cancer patients. |
|
|